MedTrace Logo

Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa

NCT02465749 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2015-06-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the role of continuous oxygen therapy combined with blue light deprivation in prevention and control of retinitis pigmentosa, in order to find a new strategy of treatment for retinitis pigmentosa.

Conditions

Interventions

DRUG

Continuous oxygen

Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;

DEVICE

blue light-absorbing sunglasses

Wearing blue light-absorbing sunglasses at daily time;

DRUG

Compound thrombosis capsule sig: 1.5g/tid

Compound thrombosis capsule sig: 1.5g/tid

DRUG

Ginkgo biloba pills sig: 300mg/tid;

Ginkgo biloba pills sig: 300mg/tid;

DRUG

Vitamin B sig: 10mg/tid

Vitamin B sig: 10mg/tid

DRUG

Vitamin AD sig: 1 tablet/tid

Vitamin AD sig: 1 tablet/tid

Sponsors & Collaborators

  • Zhujiang Hospital

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Guangzhou Jeeyor Medical Research Co.,Ltd.

    collaborator UNKNOWN

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Qianying Gao, PHD · State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02465749 on ClinicalTrials.gov